Category · Weight loss & GLP-1
Semaglutide, tirzepatide, and the new generation of weight-loss medication — without the marketing fog.
Published reviews
Compounded · Sublingual
$174/month, 503A compounded, all 50 states. The cheapest verified legal cash-pay GLP-1 in May 2026. Graded 8.5/10 across cost, intake, sourcing, screening.
Read the review →
Coming soon
Brand-name pathways (Wegovy via NovoCare, Zepbound via LillyDirect), competing compounded telehealth providers, and insurance-covered routes. One review per week.
Want a specific provider reviewed first? Drop us a line.
What every review in this category answers
We publish the all-in twelve-month math for every program — intake fee, monthly subscription, surcharges for compounded vs. brand-name, and shipping. The headline price is almost never the number you actually pay.
GLP-1 medications don't produce meaningful weight loss in week 4. They produce it in week 12. Most people quit at week 6, right before the slope of the curve steepens. We say so plainly.
The FDA's April 30, 2026 proposal removes semaglutide, tirzepatide, and liraglutide from the 503B bulks list. We track which providers still offer compounded options legally and which have switched to brand-name.
Some intakes ask only the questions that gate prescription approval. Others ask the safety-relevant ones. We complete the intake at every provider we recommend and document the difference.
Coming next in this category
We're publishing these in the order of what readers ask about most. If you want to know when a specific review goes live, drop us your email below and we'll send a one-time notification — no newsletter spam.
The evidence base
The clinical evidence base for GLP-1 weight loss is strong: the STEP and SURMOUNT trials (semaglutide and tirzepatide respectively) showed mean weight loss of 15–22% at 68–72 weeks. The literature is also clear that early discontinuation is the norm, not the exception, and that most clinical benefit accrues after week 12. Our reviews lean on these primary sources rather than provider marketing copy.